Stason Pharmaceuticals

Stason Pharmaceuticals, established in 1994 under the parent Stason Industrial Corporation (founded 1989), is a diversified pharmaceutical player with a dual focus on proprietary drug development and contract services. Its core therapeutic areas are oncology, renal, and orphan diseases, supported by a robust CDMO arm specializing in high-potency compound manufacturing for clinical and commercial supplies. The company has expanded its portfolio over time through strategic acquisitions, brand launches, and, most recently, entry into the consumer supplement manufacturing space in 2025.

Specialized high-containment manufacturing platform for highly potent compounds (OEL as low as 0.1 µg/m³), with capabilities for a wide range of dosage forms including tablets, capsules, ODTs, chewables, chewing gum, and powdered sachets.

In CDMO services, Stason competes with large global players (e.g., Lonza, Catalent) and niche potent compound specialists. In proprietary drugs, it competes with all pharma companies in oncology/renal/orphan spaces. In consumer supplements, it faces competition from large OTC brands and contract manufacturers.